Craft

Carna Biosciences

Stock Price

¥316

2024-10-29

Market Capitalization

¥5.9 B

2024-10-29

Revenue

¥579.1 M

FY, 2025

Carna Biosciences Summary

Company Summary

Overview
Carna Biosciences (カルナバイオサイエンス株式会社) is a clinical-stage biopharmaceutical company that develops small molecule drugs and provides drug discovery services. It offers kinase proteins and other protein products, assay kits, activity-based biochemical screening and profiling assay services, and cell-based assay services. The company also identifies and develops medicines for the treatment of cancer and inflammatory diseases using its kinase drug discovery platform, QuickScout.
Type
Public
Status
Active
Founded
2003
HQ
Kobe, JP | view all locations
Website
https://www.carnabio.com/english/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Kohichiro Yoshino

    Kohichiro Yoshino, President and Chief Executive Officer, Representative Director

  • Norio Aikawa

    Norio Aikawa, Head of Drug Discovery and Support Business, Head of IP and Legal Department, Director

    • Masaaki Sawa

      Masaaki Sawa, Chief Scientific Officer, Director

    • Emi Yamamoto

      Emi Yamamoto, Chief Financial Officer, Director, President of CarnaBio USA, Inc.

    LocationsView all

    2 locations detected

    • Kobe, Hyogo HQ

      Japan

      1-5-5 Minatojima-Minamimachi, Chuo-Ku

    • Natick, MA

      United States

      209 W Central St #307

    Carna Biosciences Financials

    Summary Financials

    Revenue (FY, 2025)
    ¥579.1M
    Gross profit (FY, 2025)
    ¥388.1M
    Net income (FY, 2025)
    (¥2.2B)
    Cash (FY, 2025)
    ¥516.8M
    EBIT (FY, 2025)
    (¥2.1B)
    Enterprise value
    $6.1B

    Footer menu